Adipotide (FTPP)

Cancer

Prohibitin, the receptor targeted by adipotide in adipose tissue, has also been identified on vasculature supplying certain tumors. Direct combinatorial selection in cancer patients confirmed vascular ligand-receptor interactions involving prohibitin-like targets, raising the possibility that adipotide or related constructs could be adapted for anti-tumor therapy by disrupting tumor blood supply (Staquicini et al., 2011). The anti-angiogenic mechanism — starving tissues of blood supply — is a well-established strategy in oncology, and adipotide's specificity for prohibitin-expressing endothelium represents a potential avenue for targeted cancer treatment.

Fat Loss

Adipotide was developed and advanced to phase I clinical trials in 2011 to investigate its ability to eliminate fat cells through vascular targeting. Studies in obese rhesus monkeys demonstrated that daily subcutaneous adipotide treatment over 28 days produced significant reductions in body weight, BMI, and abdominal circumference. Treated animals showed a dose-dependent decrease in white adipose tissue confirmed by MRI and DEXA imaging. Notably, adipotide-treated monkeys also exhibited reduced food consumption, suggesting secondary behavioral changes accompanying fat loss (Barnhart et al., 2011).

The targeting mechanism is mediated by prohibitin, a membrane protein demonstrated to be enriched on blood vessels supplying white adipose tissue and on certain cancer cells. Phage display experiments confirmed that adipotide's homing domain specifically associates with prohibitin on adipose vasculature (Kolonin et al., 2004). If prohibitin expression proves exclusive to fat vasculature and cancer tissue, it may serve as both a therapeutic and diagnostic target.

Clinical Research Protocols

Adipotide's clinical research history is limited but notable as one of the first vascular-targeting anti-obesity peptides to reach human trials:

Preclinical Primate Study (2011): The foundational efficacy study by Barnhart et al. used a 28-day subcutaneous injection protocol in obese rhesus monkeys (Macaca mulatta). Four obese male monkeys received adipotide at 0.43 mg/kg/day via daily subcutaneous injection. Key design features: (1) daily dosing based on allometric scaling from murine studies; (2) MRI and DEXA imaging at baseline, day 14, and day 28 to quantify white adipose tissue, lean mass, and body composition; (3) metabolic monitoring including body weight, BMI, abdominal circumference, food intake, and intravenous glucose tolerance testing (IVGTT). Results: treated animals lost an average of 11% body weight over 28 days, with significant reductions in abdominal circumference (−7 cm) and white adipose tissue on MRI. A parallel group of 6 lean monkeys served as controls and received vehicle injections. A critical observation was that treated animals showed reversible changes in renal proximal tubule cells, with serum creatinine elevations that normalized within weeks of treatment cessation. Barnhart KF et al. (2011) — Sci. Transl. Med. 3, 108ra112. PMID: 22072638

Murine Dose-Response Studies: Earlier mouse studies established the dose-response relationship for adipotide. Kolonin et al. (2004) demonstrated that intravenous or intraperitoneal administration of adipotide in diet-induced obese (DIO) C57BL/6 mice at doses ranging from 1-10 mg/kg produced dose-dependent reductions in white adipose tissue mass within 4 weeks. The initial phage display experiments that identified the CKGGRAKDC homing motif involved intravenous injection of phage libraries followed by recovery from adipose vasculature, confirming prohibitin as the vascular target. Kolonin MG et al. (2004) — Nat. Med. 10, 625-632. PMID: 15133506

Phase 1 Clinical Trial (2011-2012): Adipotide entered Phase 1 clinical evaluation for prostate cancer (rather than obesity) based on the observation that prohibitin is expressed on tumor vasculature as well as adipose vasculature. The trial was conducted at MD Anderson Cancer Center in collaboration with the University of Texas. While detailed Phase 1 results have not been published in peer-reviewed form, the trial assessed safety, tolerability, and preliminary pharmacokinetics in human subjects with advanced solid tumors. The trial focused on dose escalation to establish the maximum tolerated dose, with renal function monitoring as a primary safety concern based on the primate findings.

Key Protocol Considerations: Unlike conventional peptide therapeutics, adipotide's mechanism (vascular disruption) requires careful monitoring of off-target vascular effects. Protocols have incorporated: frequent serum creatinine and BUN measurements; urinalysis for proteinuria and tubular markers; renal imaging to detect structural changes; and serial body composition assessment by DEXA or MRI to confirm selective adipose tissue targeting.

Comparison to Related Compounds

Adipotide vs. GLP-1 Receptor Agonists: The fundamental distinction is mechanistic: GLP-1 RAs (liraglutide, semaglutide, tirzepatide) reduce body weight primarily by suppressing appetite through central nervous system and gastrointestinal effects, leading to reduced caloric intake. Weight loss is gradual (months to years) and requires ongoing treatment — cessation leads to weight regain as appetite-suppressive effects dissipate. Adipotide, by contrast, directly destroys the vasculature supplying white adipose tissue, causing irreversible fat cell death through ischemia. Theoretically, this could produce more durable fat loss since destroyed adipocytes are not readily regenerated in adults. However, GLP-1 RAs have proven cardiovascular and metabolic benefits far beyond weight loss, including demonstrated reductions in MACE, renal protection, and NASH resolution, which adipotide has not been shown to provide.

Adipotide vs. DNP (2,4-Dinitrophenol): DNP is a mitochondrial uncoupler that dissipates the proton gradient, converting caloric energy directly to heat. While highly effective for fat loss, DNP has an extremely narrow therapeutic index — overdose produces lethal hyperthermia, and chronic use causes cataracts, neuropathy, and agranulocytosis. DNP acts non-selectively on all mitochondria throughout the body. Adipotide's vascular targeting approach offers tissue selectivity that DNP completely lacks, though adipotide's renal toxicity presents its own safety challenges. DNP is banned by the FDA and is not approved for human use anywhere. Grundlingh J et al. (2011) — J. Med. Toxicol. 7, 205-212. PMID: 21739343

Adipotide vs. AOD-9604: AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH amino acids 177-191) with a tyrosine addition. It was proposed to stimulate lipolysis and inhibit lipogenesis without the diabetogenic effects of full-length hGH. However, clinical trials failed to demonstrate significant weight loss in humans, and its development was largely discontinued. Unlike adipotide's vascular disruption mechanism, AOD-9604 was hypothesized to act through direct metabolic effects on adipocytes. Neither compound has achieved regulatory approval for obesity. Heffernan MA et al. (2001) — Endocrinology 142, 5182-5189. PMID: 11713211

Ongoing & Future Research

Clinical development of adipotide has been largely dormant since the initial Phase 1 trial, and no active clinical trials are currently registered on ClinicalTrials.gov. Several factors explain this trajectory, and related research continues:

Why Development Stalled: The primary obstacle is the dose-limiting renal toxicity observed in primate studies. Proximal tubule damage — while reversible upon cessation in monkeys — represents a significant safety liability that would require either: (1) development of modified adipotide variants with reduced renal accumulation; (2) renal-protective co-therapies; or (3) targeted delivery systems (nanoparticles, antibody-peptide conjugates) that improve the therapeutic index. Additionally, the rapid advancement of GLP-1 RA therapies (semaglutide, tirzepatide) with demonstrated efficacy and manageable safety profiles reduced the urgency and commercial incentive for a riskier vascular-targeting approach.

Prohibitin Biology Research: Active basic science research continues to investigate prohibitin's role in vascular biology and cancer. Prohibitin has emerged as a multifunctional protein involved in mitochondrial chaperoning, cell cycle regulation, and transcriptional control beyond its vascular address function. Key areas of ongoing investigation include:

• Prohibitin's role in tumor angiogenesis and potential as a cancer biomarker. Thuaud F et al. (2013) — J. Med. Chem. 56, 5. PMID: 23387527
• Differential prohibitin expression across adipose tissue depots (visceral vs subcutaneous), which could enable depot-selective targeting strategies.
• Prohibitin-targeting small molecules as alternatives to peptide-based approaches, potentially overcoming the pharmacokinetic limitations of adipotide.

Next-Generation Vascular Targeting: The proof-of-concept established by adipotide has stimulated research into improved vascular-targeting strategies for obesity:

• Nanoparticle delivery: Encapsulating proapoptotic peptides in adipose-homing nanoparticles could improve pharmacokinetics, reduce renal exposure, and enhance adipose accumulation.
• Antibody-drug conjugates: Anti-prohibitin antibodies conjugated to cytotoxic payloads could provide greater specificity and longer circulation times than peptide-based approaches.
• Conditional activation: Protease-activated prodrug approaches, where the proapoptotic domain is masked until cleaved by adipose tissue-specific enzymes, could reduce off-target toxicity.

Adipose Tissue Biology: The Kolonin laboratory at the University of Texas Health Science Center continues to investigate the adipose vasculature as a therapeutic target. Recent work has explored adipose stromal vascular fraction cells as mediators of tumor growth, metabolic dysfunction, and tissue fibrosis, extending the vascular targeting concept beyond simple fat destruction. Daquinag AC et al. (2015) — PMID: 26388999

Glucose Tolerance and Insulin Sensitivity

Research has revealed that adipotide produces rapid and weight-independent improvements in glucose tolerance. In primate studies, adipotide treatment improved insulin sensitivity as measured by intravenous glucose tolerance testing (IVGTT), with treated animals showing decreased insulin secretion requirements (lower insulinogenic index) independent of total weight change. These findings indicate that the reduction in white adipose tissue itself — rather than weight loss per se — drives metabolic improvement (Kim et al., 2012).

This distinction is significant for understanding the pathophysiology of type 2 diabetes. The data suggest that white adipose tissue mass directly contributes to insulin resistance, and that targeted fat reduction can improve glucose homeostasis even without substantial changes in overall body weight. These findings open pathways for developing new interventions for pre-diabetes and type 2 diabetes.